Polycystic Kidney Diseases Drug Pipeline Research 2024: Innovative Drug Therapies to Transform Treatment Landscape [Yahoo! Finance]
Regulus Therapeutics Inc. (RGLS)
Last regulus therapeutics inc. earnings: 3/12 04:37 pm
Check Earnings Report
US:NASDAQ Investor Relations:
regulusrx.com/investors
Company Research
Source: Yahoo! Finance
The global healthcare community is anticipating significant advancements in the treatment of Polycystic Kidney Diseases (PKD) with promising drug therapies in active clinical development stages set to influence patient care and outcomes by 2024. This forward momentum is characterized by a robust pipeline featuring more than 10 pharmaceutical candidates from over 8 leading companies, collectively focusing on innovative approaches aimed at improving and tailoring treatments for patients with PKD. Stages of Progress and Integrated Therapeutic Assessment Among the most advanced therapies, candidates in Phase II clinical trials exhibit potential in addressing the unmet medical needs within the PKD landscape. A detailed therapeutic assessment reveals a diversity of products utilizing various routes of administration – oral, intravenous, subcutaneous, and others. The development of drugs ranges from recombinant fusion proteins to small molecules, highlighting a commitment to expanding t
Show less
Read more
Impact Snapshot
Event Time:
RGLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGLS alerts
High impacting Regulus Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
RGLS
News
- Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target raised by analysts at HC Wainwright from $9.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]Yahoo! Finance
- Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PR Newswire
- Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week [Yahoo! Finance]Yahoo! Finance
RGLS
Earnings
- 5/9/24 - Miss
RGLS
Sec Filings
- 6/24/24 - Form 8-K
- 5/21/24 - Form 4
- 5/21/24 - Form 4
- RGLS's page on the SEC website